Forest Laboratories, Inc. (NYSE: FRX) makes branded and generic prescription drugs. Two drugs account for the majority of Forest's total sales: Lexapro, a drug for the treatment of depression, and Namenda, a drug for the treatment of Alzheimer's disease. The patents for both drugs will expire by 2013., meaning FRX has only a few years to replace the revenue generated by these two products.
New products in Forest Laboratories' pipeline include ceftaroline, an injectable antibiotic acquired through the acquisition of Cerexa, Inc. in 2007; linaclotide, a product for the treatment of gastrointestinal disorders developed through a 50/50 co-development and marketing parntnership with Ironwood Pharmaceuticals, Inc.; and aclidinium, a drug for treating respiratory diseases to which Forest has acquired exclusive United States marketing rights through a collaborative agreement with Laboratorios Almirall SA of Spain.(Read more at Wikinvest )
- Company Overview
- Business and Financial Metrics
- Key Trends and Forces
- Forest Laboratories Gets 89% of its Sales From Only Four Drugs
- The Antidepressant Market is Populated with Numerous Products and Has Begun Slowing
- The Maturation of the Alzheimer's Drug Market Will Slow The Rate of Namenda's Sales Growth